N-终端B型亲尿素和中风床上患者的临床结果之间的关联:一个横截面研究
Dongxia Li1, Mingchao Zhou1, Fubing Zha1
1Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
BMJ open
|January 29, 2024
概括
卧床的中风患者具有更高的N-终端亲B型性尿素 (NT-pro-BNP) 水平. 低白蛋白和高高灵敏性C反应蛋白 (hs-CRP) 与这些患者的NT-pro-BNP升高有关.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 生物化学 生物化学
背景情况:
- 脑卒中幸存者往往在床上,这会影响他们的康复.
- 在中风后观察到血清N-终端B型亲尿素 (NT-pro-BNP) 的升高.
研究的目的:
- 为了比较卧床和非卧床中风患者之间的NT-pro-BNP水平.
- 确定与卧床中风患者高NT-pro-BNP相关的因素.
主要方法:
- 这是一项单一中心的横截面研究,涉及465名参与者.
- 数据收集包括临床,实验室和心声学参数.
- 用二进制物流回归和ROC曲线进行分析.
主要成果:
- 卧床患者表现出较高的NT-pro-BNP,D-二聚体和hs-CRP水平.
- 在卧床患者中,与高NT-pro-BNP相关的因素包括晚年 (≥75岁),高hs-CRP和低专蛋白.
- 在卧床患者中,hs-CRP (AUC 0.700) 和白蛋白 (AUC 0.671) 显示了高NT-pro-BNP的预测值.
结论:
- 卧床中风患者的NT-pro-BNP水平明显更高.
- 低白蛋白和高hs-CRP是该人群中高NT-pro-BNP的关键指标.
- 对风险分层和治疗策略进行进一步的研究是有必要的.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
92
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431